LifeMD: 3 Key Takeaways for Long-Term Investors

On its third quarter of 2026 earnings call, held on Nov. 12, 2026, LifeMD (NASDAQ:LFMD) announced a strategic shift toward direct pharmacy distribution of branded glucagon-like peptide-1 (GLP-1) weight-loss medications alongside lower operating expenses. For long-term investors, the transition to direct relationships with pharmaceutical manufacturers and enterprise partnerships could reduce reliance on marketing and establish durable subscription revenue. Three key takeaways from management's comments illustrate how this business transformation is unfolding.

1. Direct Pharmacy Agreements Expand Branded GLP-1 Access

LifeMD signed direct fulfillment arrangements with pharmaceutical manufacturers Eli Lilly and Novo Nordisk to deliver branded obesity treatments directly to patients through its affiliated pharmacy. By handling prescribing, fulfillment, and clinical support on a single telehealth platform, the company aims to eliminate third-party friction and capture higher gross profit dollars per subscriber.

In the last 30 days, we completed arrangements with both Eli Lilly and Novo Nordisk that enable us to integrate self-pay GLP-1 medications directly into our pharmacy operations, further expanding access to these products by removing friction from the patient experience.
-- Justin Schreiber, Chairman and Chief Executive Officer

2. Enterprise Distribution Unlocks Low-Cost Patient Acquisition

Management launched a major enterprise collaboration with telecommunications provider AT&T, granting 100 million wireless and fiber customers and 110,000 employees access to complimentary memberships. This channel provides a scalable, lower-cost alternative to traditional direct-to-consumer digital marketing.

AT&T gives us access to patients at a small fraction of the acquisition cost we typically see through paid media, places LifeMD in front of tens of millions of American households and validates our platform with one of the largest and most trusted companies in the country.
-- Justin Schreiber, Chairman and Chief Executive Officer

3. Lower Introductory Prices Drive Longer Patient Commitments

Management lowered the introductory monthly price for its weight management program from $75 to $39 to improve subscriber conversion and push patients into multi-month plans. The shift reduced customer acquisition cost (CAC), the expense required to acquire a new subscriber, while extending customer duration.

Our customer acquisition cost declined 40% from its peak in June. The share of new patients selecting multi-month plans increased from approximately 25% to approximately 85%.
-- Justin Schreiber, Chairman and Chief Executive Officer

Looking Ahead

Operating expenses are falling as automated workflows streamline administrative care, while internal pharmacy capabilities position LifeMD to capture dispensing fees across expanding prescription channels. Management expects fixed overhead to remain flat even as patient volume expands in 2027.

In closing, our cost structure is meaningfully leaner than it was at the start of the year with more improvements to come.
-- Atul Kavthekar, Chief Financial Officer

As Food and Drug Administration regulatory standards limit compounded alternatives for next-generation metabolic treatments, LifeMD's integrated clinical infrastructure positions it to capture market share among virtual care providers.

As the category moves toward next-generation branded therapies, we believe LifeMD will be one of the best positioned virtual care and pharmacy platforms in the country.
-- Justin Schreiber, Chairman and Chief Executive Officer

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.